Immersive cardiac training tech gaining ground in high-stakes procedures

Tern plc

Fundamental XR is emerging as a key player in the shift toward immersive clinical training, offering a multimodal platform designed specifically for intracardiac interventions. Instead of relying on flat-screen visuals or isolated device simulations, this system merges real-world imaging modalities, including ultrasound, CT, fluoroscopy and 3D reconstructions, into a single virtual or mixed reality environment.

This matters because traditional training models are struggling to keep up with the demands of structural heart procedures. These interventions are becoming more intricate, with tighter tolerances and rising expectations around safety and efficiency. Platforms like Fundamental XR offer hospitals and manufacturers a tool to accelerate operator readiness, reduce avoidable errors, and improve procedural consistency, all of which are directly relevant to long-term value creation in this space.

What differentiates this model is its integration of full procedural context. Trainees don’t just learn isolated movements — they simulate the entire sequence of an intracardiac case, complete with real-time feedback from multimodal imaging. That creates a more realistic environment to develop the subtle spatial and tactile judgment needed for safe catheter navigation and device deployment. It also shortens the learning curve for new devices, which is increasingly important as manufacturers push for faster adoption cycles.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Search